Toregem Biopharma is slated to begin clinical trials in July of next year after it succeeded growing new teeth in mice five years ago.

I read quickly and easily. Finally we are getting at the heart of the family and Margo’s rift with her mother. Margo gets a call from a nurse who worked with her dad.  Maybe Margo can finally solve the crime which put her father in prison. The  Angelhart Investigations series is fast paced and the […]

A new clinical trial reveals intriguing results about a potential treatment for high-risk smoldering multiple myeloma, a pre-cancerous bone marrow condition that brings an elevated risk of multiple my...

March 10, 2025: National Center for Health Research supports FDA's decision to require that a confirmatory trial is "underway" before granting accelerated approval, but the definition of underway need...

Investing.com -- Roche Holding AG (OTC:RHHVF) on Monday reported mixed results from late-stage trials for its experimental drug astegolimab, which is being developed to treat chronic obstructive pulmonary disease (COPD). According to a statement released Monday, the drug showed a 15.4% reduction in worsening of the condition, known as exacerbations, in a phase 2b study. However, astegolimab failed to meet its goal in another trial. Levi Garraway, Roche’s chief medical officer and head of global product development, said: "This was the first set of studies in an ’all-comers’ COPD population, and we will discuss these data with regulatory authorities to evaluate next steps for astegolimab." The mixed results represent a setback for the company as it works to accelerate the development of new treatments for the deadly lung condition. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Before you buy stock in ROG, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is ROG one of them?

Isomorphic Labs, the four-year-old drug discovery start-up owned by Alphabet, is poised to achieve a significant milestone in artificial intelligence […]